Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate
Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...
Physician's Weekly1d
Optimized Prescribing of SGLT2 Inhibitors and GLP-1 RAs in High-Risk Patients
The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...
Medscape7d
GLP-1 RAs Unlikely to Increase Suicide Risk
Initial reports of increased suicidality in GLP-1 RA users compared with the general population raised concerns about the risk for this rare but serious adverse event, given the rising popularity ...
Medscape26d
GLP-1 RAs Benefit Kidney Transplant Recipients With T2D
They matched each GLP-1 RA user with a kidney transplant recipient who had not started a GLP-1 RA, was alive with a functioning graft, and had accrued identical posttransplant survival time.
Hosted on MSN1mon
Many adults stop GLP-1 therapy within a year with low restart rates, analysis finds
Discontinuation was defined as 60 days without any GLP-1 RA on hand. Reinitiation was defined as the first fill of any GLP-1 RA after discontinuation. Patients were followed for up to two years ...
MPR13d
GLP-1 RA Use Tied to Better Kidney Transplant Outcomes in Patients With Diabetes
HealthDay News — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among kidney transplant recipients with diabetes, according to a study ...
Managed Healthcare Executive23h
GLP-1 Receptor Agonists Offer Less Invasive Alternative to Bariatric Surgery for CV Health in Obese Patients | ACC 2025
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.
Renal & Urology News17d
Risk for Specific Hematologic Cancers Down With GLP-1 Receptor Agonist Use in T2DM
GLP-1 RA use linked to lower risks for myelodysplastic syndromes, myeloproliferative neoplasms compared with metformin ...
Hosted on MSN2mon
Novo Nordisk's Ozempic gets FDA approval for kidney disease
Semaglutide's main competitor in the GLP-1 RA therapy market is Eli Lilly's ... ZLDPF), Terns Pharmaceuticals (TERN) and Structure Therapeutics (GPCR).
Medical Xpress26d
No link seen between preop GLP-1 receptor agonist use and postop aspiration pneumonia
No significant differences were seen in the odds of postoperative pneumonia between GLP-1 RA users and nonusers in an adjusted analysis (odds ratio, 0.78; 95% confidence interval, 0.57 to 1.06; P ...
Medical Xpress22d
Risk for specific hematologic cancers down with GLP-1 receptor agonist use in type 2 diabetes
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use in patients with type 2 diabetes is linked to a reduced risk of developing certain hematologic cancers compared to insulin and metformin.
Monthly Prescribing Reference21d
Risk for Specific Hematologic Cancers Down With GLP-1 Receptor Agonist Use in T2DM
HealthDay News — For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers compared ...